forecast incyt fve
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jun
estim jun
price data jun
rate updat jun
currenc amount express
methodolog valu compani
margin lower fair valu estim incyt
per share incorpor food
drug administr approv olumi baracitinib
mg dose mg dose propos
partner amid safeti concern limit approv
par advisori committe recommend
releas earlier april odd approv
dose found elsewher world name europ
japan narrow moat rate remain intact believ
competit advantag rest jakafi franchis
rare blood disord unrel olumi
slightli lower top-lin estim olumi
 market smaller dose could limit usag
drug among sever treatment-refractori patient
could benefit potent mg dose
olumi addit black box warn thrombocytosi
found label incumb jak inhibitor
xeljanz could also temper enthusiasm drug though
lower rel seriou infect malign seen
trial could provid small window opportun incyt
lilli base posit phase result rheumatoid
arthriti popul competitor plan file anoth
oral jak inhibitor upadacitinib fda second
half would posit drug regulatori
decis notabl upadacitinib shown high
efficaci among rheumatoid arthriti patient sign
thrombot event like olumi up-and-com
expect intensifi competit
howev sale outlook alreadi dampen
follow fda complet respons letter
advisori committe mix vote last month addit
believ rheumatoid arthriti market abl
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer
partner novarti market drug includ rheumatoid
arthriti treatment olumi licens oncolog drug
iclusig chronic myeloid leukemia pipelin includ broad array
oncolog autoimmun program includ next-gener jak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
support multipl oral therapi high degre
patient churn differ therapi sinc
receiv portion olumi sale form royalti
partner lilli revis outlook minim
impact valuat rest-of-world sale europ
japan project olumi alreadi gain
approv mg remain unaffect fda limit
olumi news abrupt flash burn
ido inhibitor program believ market
overpen compani creat attract entri
point investor jakafi label expans continu
uptak among approv popul addit
progress next-gener jak inhibitor itacitinib
biggest driver valuat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
